180
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Disruption of chromosomal locus 1p36 differentially modulates TAp73 and ΔNp73 expression in follicular lymphoma

, , , , &
Pages 2924-2931 | Received 17 Sep 2013, Accepted 27 Feb 2014, Published online: 06 May 2014

References

  • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
  • Campbell LJ. Cytogenetics of lymphomas. Pathology 2005;37: 493–507.
  • Nogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1803–1811.
  • Dave BJ, Nelson M, Sanger WG. Lymphoma cytogenetics. Clin Lab Med 2011;31:725–761.
  • Dave BJ, Hess MM, Pickering DL, et al. Rearrangements of chromosome band 1p36 in non-Hodgkin's lymphoma. Clin Cancer Res 1999;5:1401–1409.
  • Cheung KJ, Shah SP, Steidl C, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 2009;113:137–148.
  • Dominguez G, Garcia JM, Pena C, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006;24:805–815.
  • Collavin L, Lunardi A, Del SG. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010;17:901–911.
  • Bailey SG, Cragg MS, Townsend PA. Family friction as DeltaNp73 antagonises p73 and p53. Int J Biochem Cell Biol 2011;43:482–486.
  • Stoffel A, Filippa D, Rao PH. The p73 locus is commonly deleted in non-Hodgkin's lymphomas. Leuk Res 2004;28:1341–1345.
  • Stiewe T, Putzer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002;9:237–245.
  • Tannapfel A, Wasner M, Krause K, et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 1999;91:1154–1158.
  • ISCN 2013: An International System for Human Cytogenetic Nomenclature. Shaffer LG, McGowan-Jordan J, and Schmid M (eds). Basel: S. Karger, 2013.
  • Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–408.
  • Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res 2008;68:2551–2556.
  • Cheung KJ, Johnson NA, Affleck JG, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res 2010;70:9166–9174.
  • Cuadros M, Ribas G, Fernandez V, et al. Allelic expression and quantitative RT-PCR study of TAp73 and DeltaNp73 in non-Hodgkin's lymphomas. Leuk Res 2006;30:170–177.
  • Duhoux FP, Ameye G, Lambot V, et al. Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies. PLoS One 2011;6:e26311.
  • Sayan BS, Yang AL, Conforti F, et al. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci USA 2010;107:12877–12882.
  • Conforti F, Sayan AE, Sreekumar R, et al. Regulation of p73 activity by post-translational modifications. Cell Death Dis 2012; 3:e285.
  • Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010;21:133–139.
  • Rabenhorst SH, Burini RC, Schmitt FC. Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: correlation with working formulation and Kiel classification in formalin-fixed paraffin-embedded material. Pathology 1996;28:12–16.
  • Provencio M, Martin P, Garcia V, et al. Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2010;51:2021–2030.
  • Brigati C, Banelli B, Casciano I, et al. Epigenetic mechanisms regulate DeltaNP73 promoter function in human tonsil B cells. Mol Immunol 2011;48:408–414.
  • Zhang LN, Li JY, Xu W. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Ther 2013;20:1–7.
  • Toh WH, Nam SY, Sabapathy K. An essential role for p73 in regulating mitotic cell death. Cell Death Differ 2010;17:787–800.
  • Busuttil V, Droin N, McCormick L, et al. NF-kappaB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2. Proc Natl Acad Sci USA 2010;107:18061–18066.
  • Melino G, Bernassola F, Ranalli M, et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 2004;279:8076–8083.
  • Ming L, Sakaida T, Yue W, et al. Sp1 and p73 activate PUMA following serum starvation. Carcinogenesis 2008;29:1878–1884.
  • Clybouw C, Fischer S, Auffredou MT, et al. Regulation of memory B-cell survival by the BH3-only protein Puma. Blood 2011;118: 4120–4128.
  • Grande L, Bretones G, Rosa-Garrido M, et al. Transcription factors Sp1 and p73 control the expression of the proapoptotic protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin. J Biol Chem 2012;287:26495–26505.
  • Michalak EM, Jansen ES, Happo L, et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ 2009;16:684–696.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.